Recruiting NA INTERVENTIONAL 2-arm NCT06899152

HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer (HepQuant)

HepQuant: Pilot Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer

Sponsor: HepQuant, LLC

Conditions Cholangiocarcinoma Hepatocellular Cancer Hepatocellular Carcinoma Liver Cancer Liver Metastases

Interventions HepQuant DuO Multiparametric MRI Scans

Updated 6 times since 2025 Last updated: Jul 22, 2025 Started: Jul 16, 2025 Primary completion: Jul 31, 2031 Completion: Jul 31, 2031

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Cholangiocarcinoma and Hepatocellular Cancer, this trial is actively recruiting participants. The trial is conducted by HepQuant, LLC and has accumulated 6 data snapshots since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Recruiting NA
Aug 2025 — Sep 2025 [monthly]

Recruiting NA
Jul 2025 — Aug 2025 [monthly]

Recruiting NA
Jun 2025 — Jul 2025 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting
May 2025 — Jun 2025 [monthly]

Not Yet Recruiting NA

▶ Show 1 earlier version

Apr 2025 — May 2025 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

HepQuant, LLC
Montefiore Medical Center
Perspectum

Data source: Montefiore Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• The Bronx, United States